Our privacy policy describes how Fidessa uses cookies on our website. If you continue using our website, you are consenting to our use of cookies. OK

Nasdaq OMX and Burgundy make progress; LCH.Clearnet fights back

Great to see that volumes are on the rise at Nasdaq OMX. Whilst the total volumes are still quite small, the rate of increase is pretty impressive.
Nasdaq OMX Weekly Turnover €bn

Nasdaq OMX Weekly Turnover €bn

Nasdaq OMX Market Share per Index

Nasdaq OMX Market Share per Index

It seems that a combination of ultra low cost and focus around targeting specific user groups (in this case, traders of the CAC40), is paying off. As a result, the FFI of the CAC40 has risen by 8.5% in just a week. It’s probably too early to tell, but this does seem an endorsement of last week’s comment about how the European landscape might end up. Speaking with Charlotte Crosswell today she said that they were hoping to replicate this focussed approach on the DAX and that they were also seeing more order routed volume flowing through the platform too.

Also, congratulations to Burgundy on receiving FSA approval. It looks like the Nordic MTF will now begin operations in the summer. Olof Neiglick (Burgundy’s CEO) did make the point to me, however, that “SOR is new to the region” and so it will naturally take some time to build up liquidity on his platform.

In other news it appears that competition in the clearing and settlement world is hotting up (LCH.Clearnet cuts EquityClear fees). The rise of MTFs opened the door for lower cost clearers such as EMCF to step in with lower fees and it now looks like the primary CCPs are starting to fight back. The real debate, however, is about what the real shape of clearing should be. The challenge is to get the right balance between structure (horizontal or vertical), fees (utility or for profit) and, of course, risk management. Events over the past 12 months have shown that big financial institutions can disappear overnight and so the primary role of CCPs in terms of guaranteeing trades should not be overlooked.

Leave a comment

Copyright © 2018 Fidessa group plc. All rights reserved.

The information contained within this website is provided for informational purposes only. Fidessa will use reasonable care to ensure that information is accurate at the time it is made available, and for the duration that it remains on the site. The information may be changed by Fidessa at any time without notice. We also reserve the right to close the website at any time. No representation or warranty, expressed or implied, is given on behalf of Fidessa or any of its respective directors, employees, agents, or advisers as to the accuracy or completeness of the information or opinions contained herein or its suitability for any purpose and, save in the case of fraud, all liability for direct, indirect, special, consequential or other loss or damages of whatever kind that may arise from use of the website is hereby excluded to the fullest extent permitted by law. Any decisions you make based on the information in this website are your sole responsibility and information on the website should not be relied upon in connection with any investment decision.

The copyright of this website belongs to Fidessa. All other intellectual property rights are reserved.

Fragulator® is a registered trademark of Fidessa group plc.

Reproduction or redistribution of this information is prohibited except with written permission from Fidessa.